Deal of the Day — limited-time pharmacy picks!
Mitinab 400mg tablet

Mitinab 400mg tablet

Prescription requiredRx Required

Salt Composition: Imatinib

Expiry Date: 01/2028

Special offer

Buy at $11.15

$11.15

Inclusive of all taxes

▼

10 tablet(s) in a strip

About The Product

chronic myeloid leukaemia and acute lymphocytic leukaemia

Description

Mitinab 400mg tablet belongs to a class of medication known as tyrosine kinase inhibitors as it contains Imatinib as an active ingredient. It is an anticancer medicine that is commonly prescribed to treat certain blood cancers like chronic myeloid leukemia & acute lymphocytic leukemia, and gastrointestinal stromal tumors.

It works as a specific inhibitor of several tyrosine kinase enzymes. After the oral administration, the effect of this medicine can be observed in 2-4 hours.​

Uses

  • Blood cancer (Chronic myeloid leukaemia & acute lymphocytic leukemia)
  • Gastrointestinal stromal tumor

Side Effects

Like any other medicine, Mitinab 400mg tablet also has some adverse effects on the body, and most of them are manageable without special medical attention.

Some common side effects include:

  • Muscle cramp
  • Musculoskeletal (bone, muscle or joint) pain
  • Rash
  • Weight gain
  • Edema (swelling)
  • Nausea
  • Vomiting
  • Diarrhea
  • Fatigue
  • Abdominal pain
  • Bleeding
  • Breathing problems
  • Cough
  • Dizziness
  • Dry eye
  • Hemorrhage


Do not forget to discuss the risks and benefits of this medication with your doctor. Seek medical attention immediately in case of any severe issues.

How To Use

  • Take Mitinab 400mg tablet as prescribed by your doctor. Swallow it as a whole with water and don't chew, crush, or break it. This tablet should be taken with or after food.
  • Take it at the same time every day for effective results. Don't miss a dose or overdose the medicine.​​

How It Works

  • Mitinab 400mg tablet is an anti-cancer medication. It works by acting on a protein enzyme known as bcr-abl tyrosine kinases that is responsible for the uncontrolled growth of cancerous cells.
  • By inhibiting the action of this enzyme it effectively controls the growth and multiplication of cancer cells and slows down the progression of cancer.​​

Safety Advice

Alcohol

The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Mitinab 400mg tablet.

Pregnancy

Do not take Mitinab 400mg tablet without consulting the doctor in case of pregnancy.

Breast Feeding

Mitinab 400mg tablet is unsafe to use during breastfeeding as it may cause toxicity to the baby. It is safe if prescribed

Driving

Mitinab 400mg tablet may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving or operating heavy machinery.

Kidney

Consumption of Mitinab 400mg tablet should be avoided without informing the doctor if you have any kidney-related issues.

Liver

Consumption of Mitinab 400mg tablet should be avoided without informing the doctor if you have any liver-related issues.

FAQs

Mitinab tablet is used to treat certain types of cancer, such as chronic myeloid leukemia, acute lymphocytic leukemia, and gastrointestinal stromal tumors.​

References

  • Moen, M. D., McKeage, K., Plosker, G. L., & Siddiqui, M. A. A. (2007). Imatinib: a review of its use in chronic myeloid leukaemia. Drugs, 67(2), 299-320. https://pubmed.ncbi.nlm.nih.gov/17284091/
  • Sacha, T. (2014). Imatinib in chronic myeloid leukemia: an overview. Mediterranean journal of hematology and infectious diseases, 6(1), e2014007. https://pubmed.ncbi.nlm.nih.gov/24455116/
  • Manley, P. W., Cowan-Jacob, S. W., Buchdunger, E., Fabbro, D., Fendrich, G., Furet, P., ... & Zimmermann, J. (2002). Imatinib: a selective tyrosine kinase inhibitor. European journal of cancer, 38, S19-S27. https://pubmed.ncbi.nlm.nih.gov/12528769/
  • Iqbal, N., & Iqbal, N. (2014). Imatinib: a breakthrough of targeted therapy in cancer. Chemotherapy research and practice, 2014(1), 357027.
  • Deininger, M., Buchdunger, E., & Druker, B. J. (2005). The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 105(7), 2640-2653. https://pubmed.ncbi.nlm.nih.gov/15618470/
  • Peng, B., Lloyd, P., & Schran, H. (2005). Clinical pharmacokinetics of imatinib. Clinical pharmacokinetics, 44(9), 879-894.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026